Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1b/2 Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors
Bristol-Myers Squibb (BMS)
This is a non-randomised trial, in which patients will be assigned to one of seven experimental arms, receiving BMS-813160 alone or as a combination therapy. Combination therapies will include one or more of the following: Nivolumab, Nab-paclitaxel, Gemcitabine, 5-fluoroucil (5-fu), leucovorin and/or Irinotecan.